{
  "meta": {
    "publisher": "Mass Tort Marketing Agency",
    "dataset": "Cost Per Signed Retainer (CPR) Benchmark",
    "release": "2026-q1",
    "quarter": "Q1 2026",
    "temporalCoverage": "2026-01-01/2026-03-31",
    "dataAsOf": "2026-03-31",
    "published": "2026-04-24",
    "lastReviewed": "2026-06-10",
    "methodologyVersion": "1.0",
    "methodologyUrl": "https://www.masstortmarketingagency.com/benchmarks/methodology",
    "canonicalUrl": "https://www.masstortmarketingagency.com/benchmarks/depo-provera",
    "verification": {
      "status": "unverified",
      "reviewer": null,
      "statement": "No third party has reviewed this methodology or the underlying data. Mass Tort Marketing Agency sells the leads these figures price."
    },
    "vendorDisclosure": "Mass Tort Marketing Agency sells the mass tort leads these figures price. The panel is the agency's own client base and the underlying performance data is self-reported by those firms.",
    "sourcesDisclosure": "Benchmark ranges are drawn from the panel performance data cross-referenced against published industry surveys and practitioner-disclosed benchmarks. Those sources are not named in the published methodology, and how they enter the calculation is not specified.",
    "license": {
      "name": "CC BY 4.0",
      "url": "https://creativecommons.org/licenses/by/4.0/",
      "attribution": "Mass Tort Marketing Agency CPR Benchmark, https://www.masstortmarketingagency.com/benchmarks/"
    },
    "nullConvention": "A null value is never a zero and never an estimate. Every null is paired with an adjacent *Reason field stating why the value is unavailable.",
    "snapshotUrl": "https://www.masstortmarketingagency.com/benchmarks/data/2026-q1.json"
  },
  "tort": {
    "slug": "depo-provera",
    "name": "Depo Provera (meningioma)",
    "status": "Active",
    "cpr": {
      "low": 2200,
      "median": null,
      "medianUnavailableReason": "Per-tort medians are not published. The dataset carries the interquartile low and high bounds for each tort; only the national median is published as a point value.",
      "high": 3100,
      "currency": "USD"
    },
    "signedRatePct": {
      "low": 10,
      "high": 14
    },
    "qualificationTier": "Medium-High",
    "sampleSize": null,
    "sampleSizeUnavailableReason": "Per-tort sample sizes are not broken out in the published dataset. The panel total (140 firms, $180M of annual mass tort lead spend across 16 active tort categories) is published at the panel level only, so the number of firms and the spend basis behind any single row cannot be stated.",
    "confidenceInterval": null,
    "confidenceIntervalUnavailableReason": "Not computable from the published dataset. Benchmarks are published as trimmed interquartile ranges, and the per-observation values a confidence interval requires are not retained in the published figures.",
    "falloffPct": {
      "low": 16,
      "high": 20
    },
    "falloffUnavailableReason": null,
    "falloffNote": null,
    "rowUpdated": "2026-04-24",
    "rowUpdatedNote": "Rows are refreshed as a complete set each release, so every row carries the release publication date rather than an independent per-row date.",
    "qualificationCriteria": "Documented Depo Provera contraceptive injection history plus a documented meningioma diagnosis.",
    "statusAndAcquisition": "Active. The textbook narrow-but-high-value tort: criteria narrow the claimant pool significantly relative to broader women's-health torts like Hair Relaxer, and the lower end of the signed-rate band reflects legitimate qualification rejections at medical-record review. MDL criteria tightening in 2025 narrowed the exposure window and moved CPR up roughly 12-18% from 2024 levels, so firms entering in 2026 should model against the current tighter criteria rather than legacy 2023-2024 baselines. Falloff is driven primarily by meningioma diagnostic verification requirements.",
    "relatedTorts": [
      "hair-relaxer",
      "suboxone",
      "nec-baby-formula"
    ],
    "canonicalUrl": "https://www.masstortmarketingagency.com/benchmarks/depo-provera",
    "quarter": "Q1 2026"
  },
  "series": {
    "low": [
      {
        "release": "2024-q4",
        "label": "Q4 2024",
        "dataAsOf": "2024-12-31",
        "value": null,
        "valueReason": "No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026."
      },
      {
        "release": "2026-q1",
        "label": "Q1 2026",
        "dataAsOf": "2026-03-31",
        "value": 2200,
        "valueReason": null
      }
    ],
    "high": [
      {
        "release": "2024-q4",
        "label": "Q4 2024",
        "dataAsOf": "2024-12-31",
        "value": null,
        "valueReason": "No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026."
      },
      {
        "release": "2026-q1",
        "label": "Q1 2026",
        "dataAsOf": "2026-03-31",
        "value": 3100,
        "valueReason": null
      }
    ]
  },
  "annotations": [
    {
      "id": "depo-provera-criteria-tightening",
      "scope": "tort:depo-provera",
      "period": "2024/2026-q1",
      "title": "MDL criteria tightening moved CPR up 12-18%",
      "text": "MDL criteria tightening in 2025 narrowed the Depo Provera exposure window, moving cost per signed retainer up roughly 12-18% from 2024 levels. Firms entering in 2026 should model against the current tighter criteria rather than legacy 2023-2024 baselines. The 2024 baseline itself is not published as a data point, so this movement is recorded as a stated change, not as a second point in the series.",
      "source": {
        "name": "Mass Tort Marketing Agency CPR Benchmark, Q1 2026 release",
        "url": "https://www.masstortmarketingagency.com/benchmarks/methodology/",
        "date": "2026-04-24",
        "type": "internal"
      }
    }
  ]
}